Mr. Neil Moat, a leading expert in mitral valve surgery and TAVI, performed the procedures at the Royal Brompton Hospital in London, England under a compassionate use protocol in October and early November. The patients had severe mitral regurgitation that was eliminated after the procedure was performed via a trans-apical approach without cardio-pulmonary bypass (known as a trans-catheter mitral valve implantation, or TMVI).
Commenting on the procedures, Mr. Moat said, "The first patient, a 68 year old female with severe left ventricular dysfunction and severe functional (secondary) mitral regurgitation, was not considered a candidate for conventional mitral valve surgery at another UK centre. Last month, using a transapical approach, we deployed the Tendyne device, optimizing its placement to eliminate mitral regurgitation." In the second procedure, Mr. Moat stated, "We implanted the Tendyne device in a 85 year old man with prior CABG and significant renal dysfunction who had severe degenerative mitral regurgitation with chordal rupture and leaflet prolapse. The procedure went smoothly and the patient had no residual mitral regurgitation. A third patient (age 87) with severe degenerative primary mitral regurgitation recently received this novel device at the Royal Brompton, resulting in no residual mitral regurgitation and improved hemodynamics. All 3 patients made a rapid recovery with no major in-hospital complications. All the patients have been discharged to their own homes."'
Source : http://www.prnewswire.com/news-releases/tendyne-announces-successful-first-human-implants-of-the-tendyne-transcatheter-mitral-valve-implant-tmvi-300003617.html
|Scooped by Investors Europe Stock Brokers|
'Boulle Group's Tendyne is a company developing technologies for transcatheter mitral valve replacement, announced earlier in 2014 that it hadsecured $25 million in an oversubscribed Series C financing led by Apple Tree Partners, along with Boulle Group members and other existing investors. Proceeds will be used for validation of Tendyne's novel Transcatheter Mitral Valve Implant to treat mitral regurgitation, including forthcoming clinical trials. ..'